BioMedNewsBreaks

TuesdayJul 08, 2025 12:18 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform 

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer. To view the full press release, visit: https://ibn.fm/nMiOZ About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed…

Continue Reading

TuesdayJul 08, 2025 9:30 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Launches Bold AI-Driven Strategy to Reach $50 Million Valuation and Target NASDAQ Uplisting 

Fifty 1 Labs (OTC: FITY), a Nevada-based innovator in AI-driven drug repurposing and functional medicine, unveiled a strategic “Game Plan” aimed at achieving a $50 million valuation and uplisting to the OTCQB by Q1 2026, with long-term plans to join the NASDAQ Capital Market. Backed by a $350,000 insider investment and leadership salary deferrals, FITY is advancing its wholly owned subsidiary, Fifty1 AI Labs LLC, with a $1 million R&D initiative to discover repurposed treatments by May 2026. The company will launch a digital platform by July 31, 2025, pursue biotech acquisitions in the $5–10 million range, and host a…

Continue Reading

WednesdayJul 02, 2025 11:40 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Declares 25% Preferred Stock Dividend Linked to AVERSA Fentanyl Approval 

Nutriband (NASDAQ: NTRB) announced that its Board of Directors has approved a 25% preferred stock dividend, granting one preferred share for every four common shares held as of July 25, 2025, with distribution set for August 5. Each preferred share will convert to one common share upon FDA approval of the Company’s AVERSA Fentanyl product. If not converted, preferred shares will be eligible for annual cash dividends from company profits at the Board’s discretion. CEO Gareth Sheridan said the move reflects the Company’s commitment to shareholder value as it advances toward AVERSA commercialization. To view the full report, visit https://nnw.fm/NdG7s…

Continue Reading

TuesdayJul 01, 2025 9:40 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Added to Four Russell Indexes in 2025 Reconstitution

Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. CEO Gareth Sheridan called the inclusion a reflection of market recognition and momentum behind the company’s AVERSA pipeline, particularly AVERSA Fentanyl, which has potential peak annual U.S. sales between $80 million and $200 million. Russell indexes, maintained by FTSE Russell, benchmark approximately $10.6 trillion in assets and are widely used by investment managers and institutions. To view the full report, visit https://ibn.fm/wa35e About Nutriband Inc. Nutriband is primarily engaged in the development…

Continue Reading

MondayJun 30, 2025 3:52 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance

Soligenix (NASDAQ: SNGX) is at the forefront of the effort as the medical community urgently seeks alternative treatments for bacterial infections in the face of escalating antibiotic resistance. The company’s SGX943 therapy “is based on dusquetide, an Innate Defense Regulator (‘IDR’) that modulates the body’s immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and reduces inflammation, offering a broad-spectrum approach to bacterial infections,” reads a recent article. “The company’s portfolio encompasses both specialized biotherapeutics and public health solutions, targeting areas with significant unmet medical needs.” To view the full article,…

Continue Reading

MondayJun 30, 2025 1:22 pm

BioMedNewsBreaks — Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company, is leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. “Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline,” reads a recent article. “The company has three lead drug candidates in clinical development, targeting major oncology markets including non-small cell lung cancer (‘NSCLC’), triple-negative breast cancer (‘TNBC’), and non-Hodgkin’s lymphoma (‘NHL’)… Starlight Therapeutics extends Lantern’s footprint into…

Continue Reading

MondayJun 30, 2025 12:33 pm

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Appoints Andrew Mavliev as Chief Technology and Product Officer

HealthLynked (OTCQB: HLYK), a connected healthcare technology company, has named Andrew Mavliev as its new Chief Technology and Product Officer. Mavliev, a seasoned executive with over 15 years of experience in technology strategy and product development, previously served as founding CTO of Aram Meem LLC’s ToYou superapp. At HealthLynked, he will lead efforts to expand its AI-powered healthcare platform, telehealth services, and integrated medical record systems. CEO Dr. Michael Dent praised Mavliev’s track record of scaling secure, compliant DTC platforms, saying his leadership will support the company’s push for more accessible and personalized care. To view the full press release,…

Continue Reading

MondayJun 30, 2025 9:30 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs

Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light (NfL) biomarker data from its Expanded Access Protocol for ALS. The company has resubmitted a revised SAP and anticipates FDA acceptance this summer, with NfL analyses scheduled for early Q4 2025 to support a potential NDA submission under the accelerated approval pathway. Clene also confirmed two additional FDA meetings in Q3 2025: one to assess long-term ALS survival data for accelerated approval consideration and another End-of-Phase 2 Type B meeting to review…

Continue Reading

MondayJun 30, 2025 9:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Issues CEO Update, Reaffirms Commitment to Growth Following Leadership Transition

NextPlat (NASDAQ: NXPL, NXPLW) released a shareholder letter from Interim CEO expressing confidence in the company’s future following the recent passing of CEO and Chairman Charles M. Fernandez. The letter highlights internal reviews, meetings with subsidiary leaders, and plans for increased focus, coordination, and strategic investment to build on the company’s existing foundation and drive long-term value creation. To view the full press release, visit: https://ibn.fm/jGgfX About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist…

Continue Reading

FridayJun 27, 2025 10:20 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its RedTail platform—a systemically delivered virotherapy designed to target metastatic cancers and deliver genetic payloads. Preclinical data presented at AACR and ASCO showcased RedTail’s tumor selectivity and immune modulation potential, driving partnership discussions and IND-enabling studies for lead candidate CLD-401, with a filing expected by end…

Continue Reading